Table 3 Factors influencing the outcome of sunitinib therapy in SP cases

Specifications of all patients with slight progression N = 48

PFS-HR (95% CI)

p

OS-HR (95% CI)

p

Age

1.047 (1.008–1.089)

0.019

1.025 (0.982–1.069)

0.265

Number of metastatic organs

1.159 (0.873–1.538)

0.307

1.107 (0.820–1.494)

0.508

PFS-HR (95% CI)

p

OS-HR (95% CI)

p

 man/woman

3.202 (1.473–6.962)

0.003

2.077 (0.891–4.846)

0.091

 0 / 1 / 2

1 / 3.671 (0.474–28.414) / 5.304 (0.709–39.661)

0.176

1 / 2.965 (0.375–23.430) / 3.841 (0.513–28.786)

0.366

 Yes / No

1 / 0.840 (0.450–1.570)

0.585

1 / 0.724 (0.365–1.436)

0.356

 Yes / No

1 / 3.397 (1.364–8.461)

0.009

1 / 5.583 (2.135–14.601)

< 0.001

 Yes / No

1 / 2.383 (1.241–4.578)

0.009

1 / 2.479 (1.185–5.183)

0.016

 Yes / No

1 / 2.373 (1.034–5.445)

0.041

1 / 2.583 (1.008–6.709)

0.047

 2 / 1 / 0

NA

NA

1 / 6.163 (1.582–24.016) / 3.873 (1.130–13.280)

0.032